Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TELO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTelomir completes TELI acquisition for 34.4M shares, consolidates global Telomir-1 rights
Filed April 24, 2026 · Period ending April 22, 2026 · ~1 min read
Key Changes
-
high
Telomir issued 34.4 million restricted common shares to acquire TELI Pharmaceuticals, representing significant dilution to existing shareholders. The deal consolidates all worldwide rights to lead drug candidate Telomir-1 under one company.
Item 2.01 verify on EDGAR → -
high
Bayshore Trust provided $1 million cash at closing and committed up to $4 million more tied to FDA milestones, including IND acceptance and Phase 1/2 trial initiation for Telomir-1.
Item 1.01 verify on EDGAR → -
medium
The acquisition eliminates prior geographic fragmentation where North American and international rights were held separately, giving Telomir unified control over development and commercialization strategy globally.
Item 1.01 verify on EDGAR → -
medium
The 34.4 million shares were issued as restricted securities under Section 4(a)(2) and Rule 506 exemptions, meaning they were sold in a private placement without SEC registration.
Item 3.02 verify on EDGAR →
Summary
Telomir Pharmaceuticals closed its acquisition of TELI Pharmaceuticals on April 22, issuing 34.4 million restricted common shares to TELI's former shareholders. The deal was previously approved by Telomir shareholders in March. This transaction consolidates all global rights to Telomir-1, the company's lead drug candidate, eliminating a prior split where North American and international rights were held separately.
The unified structure gives Telomir full control over worldwide development and commercialization strategy. The acquisition brings immediate capital and potential future funding. Bayshore Trust, a TELI shareholder, contributed $1 million at closing and committed to invest up to $4 million more upon hitting FDA milestones—specifically IND acceptance and Phase 1/2 trial initiation for Telomir-1.
This milestone-based funding ties future capital to tangible development progress. Retail investors should watch for two things: first, the dilutive impact of 34.4 million new shares on earnings per share and voting power; second, progress toward the FDA milestones that would trigger Bayshore's additional up to $4 million investment. The IND filing and trial initiation will be key catalysts that validate the drug's development trajectory and unlock additional capital.
Section-by-Section Diff
Event · Item 2.01 — Completion of Acquisition or Disposition of Assets
8-K references Item 1.01 for acquisition/disposition details, but Item 1.01 text is not provided in this filing excerpt.
Added in current filing · verify on EDGAR →
Item 2.01. Completion of Acquisition or Disposition of Assets The information contained in Item 1.01 above is incorporated herein.
The company disclosed completion of an acquisition or disposition of assets under Item 2.01, incorporating details from Item 1.01. However, the Item 1.01 text is not included in the provided filing excerpt, so the specific transaction details, parties involved, consideration paid or received, and business rationale cannot be determined from this fragment alone.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Unregistered equity securities sold under Section 4(a)(2) exemption and Rule 506.
Added in current filing · verify on EDGAR →
The Shares were issued in reliance upon the exemption contained in Section 4(a) (2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder.
The company issued shares without registering them with the SEC, using a private placement exemption under Section 4(a)(2) and Rule 506. This typically means shares were sold to accredited investors in a private transaction. The filing references Item 1.01 for additional details, but that section is not included in the provided text.
Event · Item 9.01 — Financial Statements and Exhibits
Telomir Pharmaceuticals filed an 8-K to disclose a Commitment Agreement dated April 20, 2026.
Added in current filing · verify on EDGAR →
Commitment Agreement, dated April 20, 2026
The company entered into a Commitment Agreement on April 20, 2026. The 8-K does not provide details about the nature, parties, or terms of this agreement within the body text shown. Investors should review the full exhibit to understand the material terms and business impact.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify